JPRN-jRCTs042210167招募中2 期
An open-label, multicenter, randomized-controlled trial to evaluate the efficacy and safety of a carbohydrate-counting smartphone application with food image recognition system in patients with type 1 diabetes - CARB-LIFE
Chujo Daisuke0 个研究点目标入组 56 人开始时间: 2022年3月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 6age old 至 < 70age old（—）
- 性别
- All
入选标准
- •1. Patients with type 1 diabetes (acute onset, slowly progressive, and fulminant type 1 diabetes)
- •2. Patients who have a smartphone (iPhone: iOS12 or later)
- •3. HbA1c < 10.0%
- •4. Fasting C-peptide <0.6 ng/ml
- •5. Patients who recieved caobohydrate-counting instruction at least once
排除标准
- •1. Patients who are participating other clinical trials using glucose-monitoting devices
- •2. Patients who are not able to keep appointments to come to their hospitals
- •3. Patients who have any addictions (dependences) or psychotic disorders
研究者
相似试验
进行中（未招募）
1 期
A clinical study to evaluate safety and efficacy of a new vaccine in combination with standard treatment compared to standard treatment in patients with metastatic renal cancerEUCTR2014-004510-28-CZImmunicum Aktiebolag90
招募中
不适用
Edoxaban alone and Edoxaban with antiplatelet agent in patients with atrial fibrillation and chronic stable coronary artery diseaseKCT0003387Asan Medical Center1,000
进行中（未招募）
1 期
A clinical study to evaluate safety and efficacy of a new vaccine in combination with standard treatment compared to standard treatment in patients with metastatic renal cancerMetastatic Renal Cell CarcinomaEUCTR2014-004510-28-SEImmunicum AB90
进行中（未招募）
1 期
A clinical study to evaluate safety and efficacy of a new vaccine in combination with standard treatment compared to standard treatment in patients with metastatic renal cancerMetastatic Renal Cell CarcinomaEUCTR2014-004510-28-ESImmunicum AB90
进行中（未招募）
1 期
A clinical study to evaluate safety and efficacy of a new vaccine in combination with standard treatment compared to standard treatment in patients with metastatic renal cancerMetastatic Renal Cell CarcinomaEUCTR2014-004510-28-HUImmunicum AB90